A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization

Simple item page
dc.check.date2021-08-30
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisheren
dc.contributor.authorLanza, Juliane S.
dc.contributor.authorVucen, Sonja
dc.contributor.authorFlynn, Olivia
dc.contributor.authorDonadei, Agnese
dc.contributor.authorCojean, Sandrine
dc.contributor.authorLoiseau, Philippe M.
dc.contributor.authorFernandes, Ana Paula S.M.
dc.contributor.authorFrézard, Frédéric
dc.contributor.authorMoore, Anne C.
dc.contributor.funderConselho Nacional de Desenvolvimento Científico e Tecnológicoen
dc.contributor.funderFundação de Amparo à Pesquisa do Estado de Minas Geraisen
dc.contributor.funderAgence Nationale de la Rechercheen
dc.date.accessioned2020-07-23T12:40:00Z
dc.date.available2020-07-23T12:40:00Z
dc.date.issued2021-06-21
dc.description.abstractRe-emergence and geographic expansion of leishmaniasis is accelerating efforts to develop a safe and effective Leshmania vaccine. Vaccines using Leishmania recombinant antigens, such as LiHyp1, which is mostly present in the amastigote parasite form, are being developed as a next generation to crude killed parasite-based vaccines. The main objective of this work was to develop a LiHyp1-based vaccine and determine if it can induce protective immunity in BALB/c mice when administered using a dissolvable microneedle (DMN) patch by the skin route. The LiHyp1 antigen was incorporated into cationic liposomes (CL), with or without the TLR9 agonist, CpG. The LiHyp1-liposomal vaccines were characterized with respect to size, protein encapsulation rates and retention of their physical characteristics after incorporation into the DMN patch. DMN mechanical strength and skin penetration ability were tested. A vaccine composed of LiHyp1, CpG and liposomes and subcutaneously injected or a vaccine containing antigen and CpG in DMN patches, without liposomes, induced high antibody responses and significant levels of protection against L. donovani parasite infection. This study progresses the development of an efficacious leishmania vaccine by detailing promising vaccine formulations and skin delivery technologies and it addresses protective efficacy of a liposome-based dissolvable microneedle patch vaccine system.en
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (Grant numbers 201786/2015-0, 305659/2017-0); Fundação de Amparo à Pesquisa do Estado de Minas Gerais (Grant numbers RED-00007-14, APQ-03129-16 and MPR-01057-16); Agence Nationale da la Recherche (France) (grant number ANR-11-IDEX-0003-02)en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationLanza, J. S., Vucen, S., Flynn, O., Donadei, A., Cojean, S., Loiseau, P. M., Fernandes, A.P. S.M., Frézard, F., Moore, A. C. (2020) 'A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization', International Journal of Pharmaceutics, 586, pp. 1-14. doi: 10.1016/j.ijpharm.2020.119390en
dc.identifier.doi10.1016/j.ijpharm.2020.119390en
dc.identifier.endpage14en
dc.identifier.issn0378-5173
dc.identifier.journaltitleInternational Journal of Pharmaceuticsen
dc.identifier.urihttps://hdl.handle.net/10468/10267
dc.identifier.volume586en
dc.language.isoenen
dc.publisherElsevieren
dc.rights© 2020, Elsevier B.V. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectLeishmaniaen
dc.subjectVaccineen
dc.subjectLiposomeen
dc.subjectDissolvable microneedle patchen
dc.subjectCpGen
dc.subjectSkin immunisationen
dc.titleA TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunizationen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13048_1-s2.0-S0378517320303744-main.pdf
Size:
1.97 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmacy - Journal Articles